Zobrazeno 1 - 10
of 198
pro vyhledávání: '"Lianchun Xiao"'
Autor:
Khaled M. Elsayes, Robert A. Wolff, Kanwal Pratap Singh Raghav, Lianchun Xiao, Jeffrey S. Morris, Mohamed Elbanan, Ahmed Kaseb, S. Cheenu Kappadath, Bruno C. Odisio, Beth Chasen, James C. Yao, Chimela Ohaji, Armeen Mahvash, J. Kuban, Sunyoung S. Lee, Mohamed Abdelsalam, Rony Avritscher, Yehia I. Mohamed
Publikováno v:
Journal of Hepatocellular Carcinoma. 8:1129-1145
Ahmed Omar Kaseb,1 S Cheenu Kappadath,2 Sunyoung S Lee,1 Kanwal Pratap Raghav,1 Yehia I Mohamed,1 Lianchun Xiao,3 Jeffrey S Morris,4 Chimela Ohaji,1 Rony Avritscher,5 Bruno C Odisio,5 Joshua Kuban,5 Mohamed E Abdelsalam,5 Beth Chasen,6 Khaled M Elsay
Autor:
Koichi Takahashi, Nitin Jain, Guillermo Garcia-Manero, Lucia Masarova, Sa Wang, Courtney D. DiNardo, Naveen Pemmaraju, Guillermo Montalban Bravo, Tapan M. Kadia, Sanam Loghavi, Musa Yilmaz, Ghayas C. Issa, Koji Sasaki, Elias Jabbour, Steven M. Kornblau, Abhishek Maiti, Marina Konopleva, Lianchun Xiao, Curtis Lachowiez, Maria Adeoti, Farhad Ravandi, Michael Andreeff, Nicholas J. Short, Gautam Borthakur, Hagop M. Kantarjian, Naval Daver, Yesid Alvarado
Publikováno v:
J Clin Oncol
PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients relapse. Relapsed or refractory AML (R/R-AML) remains a particularly adverse p
Autor:
Robert A. Wolff, Lianchun Xiao, Reham Abdel-Wahab, Michael Weylandt, Manal M. Hassan, Karri Ballard, James C. Yao, Bhawana George, Asif Rashid, Liang Li, Abedul Haque, Zeya Wang, Donghui Li, Wenyi Wang, Yehia I. Mohamed, Genevera I. Allen, Ahmed Kaseb, Hesham M. Amin, Ye Emma Zohner, Jeffrey S. Morris, Kanwal Pratap Singh Raghav
Publikováno v:
Hepatology
BACKGROUND AND AIMS Therapeutic, clinical trial entry and stratification decisions for hepatocellular carcinoma (HCC) are made based on prognostic assessments, using clinical staging systems based on small numbers of empirically selected variables th
Autor:
Ying Wang, Arlene M. Correa, Boyi Gan, Randy L. Johnson, Ailing W. Scott, Cordelia Y Li, Melissa Pool Pizzi, Jeannelyn S. Estrella, Longfei Huo, Shaozhong Wei, Lianchun Xiao, Brian Weston, Namita Shanbhag, Shumei Song, Yuan Li, Wayne L. Hofstetter, Guang Lei, Lang Ma, Jaffer A. Ajani, Manoop S. Bhutani, Bin Liu, Jeffrey H. Lee, Qiongrong Chen, Jiankang Jin
Publikováno v:
Gut
ObjectiveGastro-oesophageal cancers (GEC) are resistant to therapy and lead to poor prognosis. The cancer stem cells (CSCs) and antiapoptotic pathways often confer therapy resistance. We sought to elucidate the antitumour action of a BCL-2 inhibitor,
Autor:
Aliya Qayyum, Yusuf Karakas, Manal M. Hassan, Hesham M. Amin, Ahmed Kaseb, Sahin Lacin, Yehia I. Mohamed, Suayib Yalcin, Asif Rashid, Lianchun Xiao, Jeffrey S. Morris
Publikováno v:
Journal of Hepatocellular Carcinoma. 7:143-153
Background The Child-Turcotte-Pugh score (CTP) is the most commonly used tool to assess hepatic reserve and predict survival in hepatocellular cancer (HCC). The CTP stratification accuracy has been questioned and attempts have been made to improve th
Autor:
Kanwal Pratap Singh Raghav, Milind Javle, Robert A. Wolff, Lianchun Xiao, Michael J. Overman, Chirayu Mohindroo, Florencia McAllister, Rachna T. Shroff, Jane E. Rogers, David R. Fogelman, Gauri R. Varadhachary, Shubham Pant, Jonathan D. Mizrahi
Publikováno v:
Cancer Medicine, Vol 9, Iss 15, Pp 5406-5415 (2020)
Cancer Medicine
Cancer Medicine
Background Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m2 IV over 30 minutes + NabP 125 mg/m2 IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocar
Autor:
Ghayas C. Issa, Koichi Takahashi, Prithviraj Bose, Elias Jabbour, Steven M. Kornblau, Hagop M. Kantarjian, Jorge E. Cortes, William G. Wierda, Zeev Estrov, Maro Ohanian, Nitin Jain, Naval Daver, Srdan Verstovsek, Naveen Pemmaraju, Yesid Alvarado, Gautam Borthakur, Jing Ning, Alessandra Ferrajoli, Courtney D. DiNardo, Guillermo Garcia-Manero, Lianchun Xiao, Farhad Ravandi, Kiran Naqvi, M. Andreeff, Tapan M. Kadia
Publikováno v:
Leukemia. 34:2914-2924
CPX-351 is a liposomal formulation of cytarabine/daunorubicin with a 5:1 fixed molar ratio. We investigated the safety and efficacy of escalating doses of CPX-351 in patients with acute myeloid leukemia (AML) at high risk of induction mortality with
Autor:
Debra Nana Yeboa, Laurence D. Rhines, David Boyce-Fappiano, Behrang Amini, Claudio E. Tatsui, Olsi Gjyshi, Andrew J. Bishop, Ahmed Kaseb, Ethan B. Ludmir, Todd A. Pezzi, Amol J. Ghia, Lianchun Xiao, Tina Marie Briere, Jing Li
Publikováno v:
Journal of Neuro-Oncology. 148:327-334
Dose escalation via stereotactic radiation therapy techniques has been necessary for hepatobiliary malignancies in the primary and oligometastatic setting, but such dose escalation is challenging for spine metastases due to spinal cord proximity. Her
Autor:
Nora M. Navone, Paul G. Corn, Sumit K. Subudhi, Mark Titus, Cristian Coarfa, Graciela M. Nogueras-Gonzalez, Amado J. Zurita, Christopher J. Logothetis, Patricia Troncoso, Shixia Huang, Shi Ming Tu, Theocharis Panaretakis, Sumankalai Ramachandran, Kimal Rajapakshe, Sue Hwa Lin, Gary E. Gallick, Eleni Efstathiou, Lianchun Xiao, Guocan Wang, Ana Aparicio, Miao Zhang
Publikováno v:
Clinical Cancer Research. 26:990-999
Purpose: Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy
Autor:
Michael J. Overman, Ryan W. Huey, Aurelio Matamoros, Kanwal Pratap Singh Raghav, Jeannelyn S. Estrella, Lianchun Xiao, Gauri R. Varadhachary, Shalini Makawita
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Cancer
BMC Cancer
Background Sarcomatoid carcinoma of unknown primary (SCUP) is a rare entity of either poorly differentiated carcinoma with sarcoma-like differentiation or a true mixed lineage neoplasm. Limited data regarding clinicopathological profile and managemen